WASHINGTON--The NHLBI (National Heart, Lung, and Blood Institute)
has reduced its support for the NCI's tamoxifen (Nolvadex) prevention
trial, saying that the enrollment may not produce useful cardiovascular
Although the primary purpose of the trial is to determine tamoxifen's
ability to prevent breast cancer in high-risk women, the trial
also hopes to show whether the agent can lower the risk of osteoporosis
and myocardial death.
The NHLBI's director Claude Lenfant told the NCI that the enrollment
to date does not include enough women over age 55 or minority
women, populations that have an increased risk for cardiovascular
disease. The NHLBI, which had originally pledged $8 million toward
the study, will now put up only $3 million, $1.8 million of which
has already been spent.